Your browser doesn't support javascript.
loading
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer, Catherine; Miranda, Elena; Dunmore, Rebecca; Liarte Marin, Elena; Beloki, Lorea; Rassl, Doris; Parfrey, Helen; Carruthers, Alan; Chahboub, Amina; Koch, Sofia; Güler-Gane, Gülin; Kuziora, Michael; Lewis, Arthur; Murray, Lynne; May, Richard; Clarke, Deborah.
Afiliação
  • Overed-Sayer C; Regeneration, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom catherine.overed-sayer@astrazeneca.com.
  • Miranda E; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Dunmore R; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Liarte Marin E; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Beloki L; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Rassl D; Royal Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, UK.
  • Parfrey H; Royal Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, UK.
  • Carruthers A; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Chahboub A; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Koch S; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Güler-Gane G; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Kuziora M; Translational Science, Early Oncology, Oncology Bioinformatics, AstraZeneca, Gaithersburg, Maryland, USA.
  • Lewis A; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Murray L; Regeneration, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • May R; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Clarke D; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Thorax ; 75(9): 754-763, 2020 09.
Article em En | MEDLINE | ID: mdl-32709610
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sobrevivência Celular / Inibidores de Proteínas Quinases / Fibrose Pulmonar Idiopática / Fibroblastos / Indóis / Mastócitos Tipo de estudo: Prognostic_studies Limite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sobrevivência Celular / Inibidores de Proteínas Quinases / Fibrose Pulmonar Idiopática / Fibroblastos / Indóis / Mastócitos Tipo de estudo: Prognostic_studies Limite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article